A Kononoff, S Hörkkö, P Pussinen, H Kautiainen, P Elfving, E Savolainen, L Arstila, H Niinisalo, J Rutanen, O Marjoniemi & O Kaipiainen-Seppänen (2021) Antibodies to malondialdehyde-acetaldehyde modified low-density lipoprotein in patients with newly diagnosed inflammatory joint disease, Scandinavian Journal of Rheumatology, 50:2, 113-117, DOI: 10.1080/03009742.2020.1795244
Antibodies to malondialdehyde-acetaldehyde modified low-density lipoprotein in patients with newly diagnosed inflammatory joint disease
|Author:||Kononoff, A.1; Hörkkö, S.2,3; Pussinen, P.4;|
1Department of Medicine, Kuopio University Hospital, Kuopio, Finland
2Institute of Diagnostics, Medical Microbiology and Immunology, Research Unit of Biomedicine, Oulu, Finland
3University of Oulu & Medical Research Center and Nordlab Oulu, Oulu University Hospital, Oulu, Finland
4Oral and Maxillofacial Diseases, University of Helsinki, Helsinki
5Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland
6Unit of Family Practice, Central Finland Central Hospital, Jyväskylä, Finland
7Department of Medicine, Iisalmi Hospital, Iisalmi
8Department of Medicine, Varkaus Hospital, Varkaus, Finland
9Suonenjoki Health Centre, Suonenjoki, Finland
|Online Access:||PDF Full Text (PDF, 0.2 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022040727483
|Publish Date:|| 2022-04-07
Objective: To assess antibodies to malondialdehyde–acetaldehyde-modified low-density lipoprotein (MAA-LDL) in patients with newly diagnosed inflammatory joint disease.
Method: Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and undifferentiated arthritis (UA), participating in the Northern Savo 2010 Study, were evaluated for metabolic syndrome (MetS), metabolic and inflammatory markers, antibodies to MAA-LDL, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis.
Results: Among 135 newly diagnosed untreated patients, of whom 53 (39%) were diagnosed to have RA, 44 (33%) SpA, and 38 (28%) UA, 49%, 30%, and 47%, respectively, had MetS. After adjusting for age and gender, anti-MAA-LDL immunoglobulin (Ig)A (p = 0.009), IgG (p = 0.031), and IgM (p = 0.001) levels differed between the diagnostic categories, but not in patients with MetS present or absent. All antibody classes to MAA-LDL correlated with erythrocyte sedimentation rate (ESR), and IgA and IgG antibodies with high-sensitivity C-reactive protein (hs-CRP). IgA antibodies to MAA-LDL correlated with rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs), fasting plasma glucose, IgA antibodies to A. actinomycetemcomitans, and in IgA and IgG antibodies to P. gingivalis.
Conclusions: Among various arthritis groups, antibodies to MAA-LDL were most common in RA. Antibodies to modified lipoproteins were associated with inflammation measured by ESR and hs-CRP. IgA antibodies to MAA-LDL correlated with age, antibodies to periodontal bacteria, RF, ACPA, and fasting glucose. Associations between antibodies to MAA-LDL and antibodies to periodontal bacteria, RA-associated antibodies, inflammatory parameters, and plasma glucose already reflect cardiovascular burden in inflammatory joint diseases at diagnosis.
Scandinavian journal of rheumatology
|Pages:||113 - 117|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
This work was supported by the Finnish Cultural Foundation, Northern Savo Regional Fund (AK, OKS); Sigrid Juselius Foundation (SH); the Finnish Rheumatism Association (AK, OKS); the Finnish Foundation for Cardiovascular Research (SH); the Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding (AK, OKS); and the Rheumatism Research Foundation (AK, OKS).
© 2021 Informa UK Limited, trading as Taylor & Francis Group. This is an Accepted Manuscript of an article published by Taylor & Francis in Scandinavian Journal of Rheumatology on 28 Sep 2020, available online: https://doi.org/10.1080/03009742.2020.1795244.